CSL Limited announced the cessation of 50,194 securities due to the lapse of conditional rights, as the conditions were not met or became unachievable. This development may impact the company’s ...
In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...
16hon MSN
First-in-human trial of CRISPR gene-editing therapy safely lowers cholesterol and triglycerides
In a 15-patient, Phase 1, first-in-human trial, a one-time CRISPR-Cas9 gene-editing therapy safely reduced LDL cholesterol ...
CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback